Overview
IPHA market data
Price History
IPHA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.55 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.24 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,103.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.03 – $2.28 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $204.1M · P/B 18.20 · P/S 45.78.
Company News
12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · Aug 14, 2026, 12:06 PM
Innate Pharma shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $8 to $9.Benzinga · Aug 12, 2026, 3:09 PM
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9Benzinga · Aug 12, 2026, 9:29 AM
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7Benzinga · Aug 10, 2026, 6:04 PM
Innate Pharma shares are trading higher after the company announced it has entered into a strategic partnership with Swedish Orphan Biovitrum AB to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma.Benzinga · Aug 10, 2026, 2:40 PM
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer TherapyBenzinga · Aug 10, 2026, 2:03 PM
12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · Aug 10, 2026, 12:06 PM
Market-Moving News for August 10thBenzinga · Aug 10, 2026, 11:18 AM
Innate Pharma Partners With Sobi To Advance Lacutamab Toward Phase 3, Targets Accelerated Approval Filing In Sézary SyndromeBenzinga · Aug 10, 2026, 7:33 AM
Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data ReadoutBenzinga · Jul 21, 2026, 5:28 AM